Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), is proud to announce its selection as a winner in the Small Molecule Dosage Form – International category, and a Finalist for a Champion Award at the 2025 CDMO Leadership Awards.
The CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect, honour top CDMOs that have demonstrated exceptional performance as determined by direct feedback from pharmaceutical and biotech companies that work with CDMOs, making this a true reflection of industry trust and performance.
Nikki Whitfield, Chief Executive Officer of Upperton Pharma Solutions, said:
“Being recognised as a winner in the 2025 CDMO Leadership Awards is a testament to the hard work and dedication of our entire team and highlights not only our continued business growth but also reflects the importance we place on the relationships we build and nurture with our customers. What makes this especially meaningful is that the recognition comes from our industry peers, reinforcing the trust our clients place in us to continually deliver exceptional projects and service as part of their drug development journey.”
Louis Garguilo, Chief Editor of Outsourced Pharma added:
Louis Garguilo, Chief Editor of Outsourced Pharma added: “For the 14th annual Outsourced Pharma CDMO Leadership Awards, we’ve added innovation to the way we select award winners, and excitement to how we will reveal those winners. The innovation comes with new award categories and enhanced scoring methodology. The added excitement is because our final Champion Award winners will only be revealed at our NYC event on March 19th. We are still the most important development and manufacturing outsourcing awards in the industry. But now more meaningful than ever.”
Upperton Pharma Solutions specialises in formulation development, clinical trial manufacturing, and commercial manufacturing across various dosage forms, including oral solids, liquids, semi-solids, and inhalation products. With a state-of-the-art 50,000 sq ft facility in Nottingham and a new 7,000 sq ft sterile manufacturing facility, the company offers integrated CDMO services from pre-clinical development through to market supply.
The 2025 CDMO Leadership Awards ceremony is scheduled for Wednesday, March 19, 2025, at THE POOL in New York City where the CDMO Champion of each category will be revealed. This event will bring together industry leaders to celebrate excellence in pharmaceutical outsourcing and development.
–ENDS-
Notes to editors:
About Upperton Pharma Solutions:
Upperton has over 25 years’ experience of delivering science-led, high quality, innovative drug development and manufacturing solutions to pharmaceutical and biotechnology clients worldwide.
Based in Nottingham, UK, Upperton has a 50,000 sq. ft development and manufacturing facility, with formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and quality control testing capability. Upperton is MHRA Approved to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which addresses both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.
The company employs around one hundred highly skilled personnel and has its headquarters in Nottingham, UK.
